CRIS Current Research Information System

OTTAVIANI, EMANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 9.814
NA - Nord America 9.780
EU - Europa 7.505
AF - Africa 615
SA - Sud America 500
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 9
Totale 28.239
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.626
VN - Vietnam 2.851
CN - Cina 2.465
SG - Singapore 2.460
GB - Regno Unito 2.059
SE - Svezia 1.198
IT - Italia 1.022
DE - Germania 899
HK - Hong Kong 580
FR - Francia 477
IN - India 426
RU - Federazione Russa 362
BR - Brasile 342
IE - Irlanda 267
NL - Olanda 240
KR - Corea 211
UA - Ucraina 174
ZA - Sudafrica 173
JP - Giappone 168
TG - Togo 146
FI - Finlandia 141
EE - Estonia 139
BD - Bangladesh 116
GR - Grecia 104
NG - Nigeria 104
CH - Svizzera 101
CA - Canada 98
CI - Costa d'Avorio 93
JO - Giordania 82
BG - Bulgaria 81
AR - Argentina 69
PH - Filippine 67
BE - Belgio 59
SC - Seychelles 50
IR - Iran 46
TH - Thailandia 45
AT - Austria 42
IQ - Iraq 42
PL - Polonia 42
TR - Turchia 39
ID - Indonesia 37
TW - Taiwan 28
UZ - Uzbekistan 27
ES - Italia 26
MX - Messico 26
EC - Ecuador 22
SA - Arabia Saudita 20
MY - Malesia 19
PK - Pakistan 17
PE - Perù 15
PY - Paraguay 13
AU - Australia 12
CL - Cile 12
EG - Egitto 11
LB - Libano 11
VE - Venezuela 11
RO - Romania 10
CO - Colombia 9
HR - Croazia 8
KE - Kenya 8
LT - Lituania 8
EU - Europa 7
PT - Portogallo 7
TM - Turkmenistan 7
ET - Etiopia 6
KZ - Kazakistan 6
MA - Marocco 6
MU - Mauritius 6
AE - Emirati Arabi Uniti 5
CZ - Repubblica Ceca 5
IL - Israele 5
OM - Oman 5
TN - Tunisia 5
TT - Trinidad e Tobago 5
AL - Albania 4
BB - Barbados 4
CR - Costa Rica 4
DK - Danimarca 4
MK - Macedonia 4
NP - Nepal 4
NZ - Nuova Zelanda 4
SI - Slovenia 4
AZ - Azerbaigian 3
CY - Cipro 3
GY - Guiana 3
HN - Honduras 3
JM - Giamaica 3
KG - Kirghizistan 3
MD - Moldavia 3
PS - Palestinian Territory 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
DZ - Algeria 2
GT - Guatemala 2
KH - Cambogia 2
LV - Lettonia 2
Totale 28.210
Salva come PNG Salva come JPEG
Città #
Southend 1.887
Singapore 1.705
Ashburn 1.019
Dong Ket 917
Chandler 841
Fairfield 820
San Jose 621
Hong Kong 551
Houston 467
Ho Chi Minh City 442
Wilmington 409
Beijing 396
Hefei 395
Woodbridge 388
Seattle 384
Hanoi 380
Ann Arbor 375
Santa Clara 323
Princeton 319
Cambridge 295
Dublin 266
Boardman 220
Bologna 190
Westminster 164
Seoul 163
Lauterbourg 160
Padova 156
New York 155
Los Angeles 151
Lomé 146
Nanjing 146
Tokyo 145
Helsinki 114
Medford 111
Milan 104
Abidjan 93
Amman 81
Bern 81
Saint Petersburg 79
Jinan 78
Sofia 78
Shenyang 77
Dallas 74
Munich 70
Abeokuta 69
Frankfurt am Main 69
Buffalo 68
Bremen 65
Haiphong 65
Hebei 62
Berlin 61
Da Nang 61
Brussels 58
Jacksonville 58
São Paulo 58
Nanchang 57
Changsha 55
Redondo Beach 55
Turin 54
San Diego 49
Shanghai 43
Tianjin 42
Florence 40
Council Bluffs 39
Redwood City 38
Bengaluru 37
Guangzhou 36
Jiaxing 35
Falls Church 34
Rome 34
Zhengzhou 31
Orem 30
Hangzhou 29
Toronto 29
Athens 26
Hải Dương 25
Johannesburg 25
London 25
Vienna 25
Biên Hòa 24
Xi'an 24
Phoenix 23
Falkenstein 22
Paris 22
Turku 22
Amsterdam 21
Ningbo 21
Norwalk 21
Bangkok 20
Montreal 19
Taizhou 19
Warsaw 19
Chengdu 18
Chicago 18
Mountain View 18
Taiyuan 18
Can Tho 17
Jakarta 17
Nuremberg 17
Istanbul 16
Totale 18.039
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 355
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 349
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 345
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 337
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 305
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 295
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 287
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 275
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 273
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 268
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 260
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 256
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 256
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 250
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 249
Assessment of the interlaboratory variability and robustness of JAK2V617Fmutation assays: A study involving a consortium of 19 Italian laboratories 247
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 244
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 241
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 235
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 234
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 232
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 229
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 227
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 227
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 223
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 221
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 219
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 217
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 213
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 209
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 209
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 207
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 205
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 204
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 203
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 202
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 200
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 200
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 200
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 199
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 195
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 195
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 192
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 192
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 191
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 191
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 191
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 190
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 189
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 188
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 187
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 186
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 186
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia 185
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 184
NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. 183
Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. 183
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 183
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure 182
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 181
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 178
FROM DIAGNOSIS TO RELAPSE: AN HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING ANALYSIS OF PAIRED DIAGNOSIS-RELAPSE SAMPLES IN BCR-ABL1-POSITIVE ALL INDICATES INVOLVEMENT OF ALTERATIONS TARGETING KEY REGULATORS OF TUMOR SUPPRESSION, CELL CYCLE CONTROL, AND LYMPHOID/B CELL DEVELOPMENT 177
Clec12a: A new AML stem cell-associated antigen 177
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 177
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 176
A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 176
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting 173
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 173
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT) 173
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 173
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. 173
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 172
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 172
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 170
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 169
SNP array reveals a new deletion of JAK2 in AML patients 169
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 168
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 167
Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells 165
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 165
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 164
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 163
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 163
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 163
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 163
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 163
GENETIC VARIATIONS IN ADH1A AND CYP2E1 STRONGLY AFFECTS RESPONSE AND TOXICITY TO A COMBINATION OF GEMTUZUMAB OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN IN CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS 161
THE RS564398, A POLYMORPHISM IN “THE ANTISENSE NON-CODING RNA IN THE INK4 LOCUS”, ANRIL, IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) SUSCEPTIBILITY 161
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 161
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 160
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 159
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 159
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 159
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 159
Genomic wide microarray analysis identifies novel copy number alterations in adult acute myeloid leukemia 159
You have accessA New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 159
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 158
WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. 158
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. 157
Evaluation of the Diasorin Q-Lamp technology for the molecular diagnosis of the philadelphia positive leukemias: an italian multicenter study 156
Totale 20.209
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.820
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.820
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.261 0 0 0 0 0 0 0 0 0 0 0 1.261
2021/20223.331 357 70 216 322 329 221 58 187 150 255 597 569
2022/20233.509 416 568 174 487 225 282 107 193 569 86 254 148
2023/2024914 35 149 39 91 49 211 61 64 59 45 63 48
2024/20253.570 137 548 292 249 459 154 331 106 35 318 164 777
2025/20268.934 746 772 720 542 940 475 789 383 2.132 827 341 267
Totale 28.747